SCHEMBL4970522

SCHEMBL4970522

CCOC(=O)C1C(=O)CCc2cc(-c3ccc(C#N)cc3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.40
HRH2 P25021 2/20 0.40
HRH1 P35367 2/20 0.40
HSD17B3 P37058 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
PPARA Q07869 2/20 0.38
PPARD Q03181 1/20 0.38
PPARG P37231 1/20 0.36
KCNH2 Q12809 1/20 0.36
PGR P06401 1/20 0.36
GAA P10253 1/20 0.36
ELANE P08246 2/20 0.36
CYP3A4 P08684 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
MCHR1 Q99705 2/20 0.35
CYP2C9 P11712 1/20 0.35
PTGER4 P35408 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970874 0.91 GRM5 (0.39) CYP11B1CYP11B2PPARAPPARDGAA
SCHEMBL4974228 0.87 MEN1 (0.41) GAACYP2C9
SCHEMBL4970905 0.86 ATM (0.43) PPARDL3MBTL1
SCHEMBL4972012 0.84 ALDH1A1 (0.41) HRH2HRH1HSD17B3PPARGGAA
SCHEMBL4975262 0.79 HSD17B10 (0.44) CYP3A4CYP2C9
SCHEMBL4972770 0.77 TDP2 (0.52) GAA
SCHEMBL4740754 0.77 MAPK1 (0.44) GAA
SCHEMBL4973505 0.76 KDM4E (0.46) PPARDPPARG
SCHEMBL4969649 0.73 HPGD (0.43) GAAL3MBTL1
SCHEMBL27677017 0.73 PGR (0.44) HRH3HRH2HRH1HSD17B3CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008118790-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-10-02 WO disclosed
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234327-A1 DIHYDROINDAZOLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC40A1, HAMP HRH3 393/4885HRH2 512/4885HRH1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.